| Not Yet Recruiting | The Effect of Probiotics vs Activated Charcoal in the Management of CKD Patients Suffering From Uremic Pruritu NCT06579066 | Ain Shams University | Phase 2 |
| Completed | Fexofenadine Versus Gabapentin for Uremic Pruritus in Patients on Regular Hemodialysis NCT06466421 | Tanta University | Phase 4 |
| Recruiting | Phase 3 Study of QLG2198 in Haemodialysis Chinese Adult Subjects With Moderate-to-Severe Pruritus NCT06446310 | Qilu Pharmaceutical (Hainan) Co., Ltd. | Phase 3 |
| Completed | The Efficacy of Hemp-containing Cream Versus Placebo in the Treatment of Uremic Pruritus NCT06159686 | Thammasat University Hospital | Phase 1 / Phase 2 |
| Completed | Phase 3 Study of Difelikefalin in Haemodialysis Chinese Adult Subjects With Moderate-to-Severe Pruritus NCT05885737 | Vifor Fresenius Medical Care Renal Pharma | Phase 3 |
| Unknown | A Study of Thalidomide in the Treatment of Refractory Uremic Pruritus NCT05525234 | RenJi Hospital | Phase 4 |
| Unknown | Using of Extra Virgin Olive Oil in Hemodialysis Patients to Improve Pruritus and Sleep Disorders NCT05466045 | National Taipei University of Nursing and Health Sciences | N/A |
| Completed | Acupressure on Uremic Pruritus and Sleep Quality Among Patients Receiving Hemodialysis NCT05575193 | National Taipei University of Nursing and Health Sciences | N/A |
| Completed | A Phase III Clinical Study of MR13A9 in Hemodialysis Patients With Pruritus. NCT04711603 | Kissei Pharmaceutical Co., Ltd. | Phase 3 |
| Unknown | The Treatment Effect of Chinese Medicine Formula on Uremic Pruritus NCT04650750 | Chang Gung Memorial Hospital | EARLY_Phase 1 |
| Unknown | A Multi-site Bridging Study of Nalfurafine Hydrochloride Orally Disintegrating Tablet NCT04728984 | Shenyang Sunshine Pharmaceutical Co., LTD. | Phase 3 |
| Completed | A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of HSK21542 Injection in Subjects Undergoing Hem NCT04470154 | Haisco Pharmaceutical Group Co., Ltd. | Phase 2 |
| Completed | AST-120 in Hemodialysis Patients With Uremic Pruritus NCT04639674 | Conmed Pharmaceutical & Bio-Medical Corporation | Phase 4 |
| Terminated | Study to Investigate the Safety of LT5001 Drug Product for Uremic Pruritus in Hemodialysis Patients NCT04393675 | Lumosa Therapeutics Co., Ltd. | Phase 1 / Phase 2 |
| Completed | CR845-CLIN3105: A Study to Evaluate the Safety and Effectiveness of CR845 in Hemodialysis Patients With Modera NCT03998163 | Cara Therapeutics, Inc. | Phase 3 |
| Completed | A Clinical Study of MR13A9 in Hemodialysis Patients With Pruritus. NCT03802617 | Kissei Pharmaceutical Co., Ltd. | Phase 2 |
| Completed | CR845-CLIN3103: A Global Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Mode NCT03636269 | Cara Therapeutics, Inc. | Phase 3 |
| Completed | Comparison of Gabapentin With Doxepin in the Management of Uremic Pruritus NCT03758079 | University of Balamand | Phase 4 |
| Completed | Safety and Efficacy of PG102P for Uremic Pruritus in HD Patients NCT03576235 | Seoul National University Boramae Hospital | N/A |
| Completed | A Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus NCT03422653 | Cara Therapeutics, Inc. | Phase 3 |
| Completed | Extension Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus NCT03281538 | Cara Therapeutics, Inc. | Phase 3 |
| Completed | TRK-820 Study in Subjects on Hemodialysis With or Without Uremic Pruritus NCT03002233 | Toray Industries, Inc | Phase 1 |
| Completed | Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus NCT02858726 | Cara Therapeutics, Inc. | Phase 2 / Phase 3 |
| Completed | Treatment of Uremic Pruritus With PA101B NCT02696499 | Patara Pharma | Phase 2 |
| Completed | Open Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic Pruritus NCT02143973 | Trevi Therapeutics | Phase 2 / Phase 3 |
| Completed | Safety and Pharmacokinetics of IV CR845 in Hemodialysis Patients, and Its Efficacy in Patients With Uremic Pru NCT02229929 | Cara Therapeutics, Inc. | Phase 2 |
| Completed | Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus NCT02143648 | Trevi Therapeutics | Phase 2 / Phase 3 |
| Unknown | Pregabalin for the Treatment of Uremic Pruritus NCT01852318 | National Taiwan University Hospital | Phase 4 |
| Completed | Phase 1 Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus NCT02373215 | Trevi Therapeutics | Phase 1 |
| Terminated | Efficacy and Safety of MT-9938 for Treatment of Uremic Pruritus in Subjects With End-stage Renal Disease Recei NCT01660243 | Toray Industries, Inc | Phase 2 |
| Unknown | Efficacy of Pregabalin in the Management of Chronic Uremic Pruritus NCT01073501 | Shaare Zedek Medical Center | Phase 4 |
| Unknown | A Randomized-Withdrawal Phase 3 Study Evaluating the Safety and Efficacy of Oral Nalfurafine HCl (AC-820)in Su NCT00793156 | Acologix, Inc. | Phase 3 |
| Completed | The Effect of Phototherapy on Pruritus of Patients With Chronic Kidney Disease NCT00494975 | National Taiwan University Hospital | N/A |
| Unknown | Treatment of Uremic Pruritus by Olive-omega 3 Ointment NCT01447693 | Assaf-Harofeh Medical Center | Phase 1 / Phase 2 |
| Approved For Marketing | Intermediate-Size Patient Population Expanded Access Program for Intravenous Difelikefalin NCT05031546 | Cara Therapeutics, Inc. | — |